Related Experiment Video
Updated: Jul 5, 2026
A Protocol for Transcranial Photobiomodulation Therapy in Mice
Published on: November 18, 2018
Photobiomodulation to prevent oral mucositis and physical function impairments after hematopoietic cell
Tomas López-Espinoza1, Paulina Araya-Castro2, Lizette Gutiérrez-Silva1
1Clínica Dávila, Santiago, Chile.
Aim:
To assess the effectiveness of photobiomodulation, compared to standard care, to prevent oral mucositis and functional impairment, and improve quality of life in adults who underwent hematopoietic cell transplantation (HCT).
Methods:
Randomized, controlled clinical trial with 30 patients with hematologic malignancies.
Intervention:
InGaIP diode laser treatment, starting on the first day of conditioning until day + 3, three times a week.
Parameters:
wavelengths of 660 nm and 808 nm, 100 mW, 2 J, 20 points.
Outcome Measures:
oral mucositis (WHO scale), functional capacity (2-min step test), handgrip strength (Jamar dynamometer), lower limb strength (Sit-to-Stand test), quality of life (FACT-BMT), and acceptance (0-10 numerical scale).
Results:
Participants fully adhered to the intervention (n = 15; 100%). Acceptance was rated 10/10 by 93.3% of participants. Severe oral mucositis occurred in 26.6% of the control group and 0% of the photobiomodulation group (p = 0.032). No significant differences were found between the groups in hospitalization days, handgrip strength, aerobic capacity, or lower-limb strength.
Conclusions:
Photobiomodulation was associated with a lower occurrence of severe oral mucositis but did not affect physical function or quality of life at discharge. Acceptance in the Chilean context was very high.
Trial Registration:
ClinicalTrials.gov: NCT06260111.
